Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HU-53
- Development stage
- Preclinical
- Lead developer
- Hebrew University of Jerusalem
- Modality
- Small Molecules
01
Overview
HU-53 is an experimental, selective neuronal nitric oxide synthase (nNOS) inhibitor developed by the Hebrew University of Jerusalem. It is designed to reduce nitric oxide (NO) levels and alleviate nitrosative stress. In preclinical studies, HU-53 has demonstrated the ability to reverse autistic phenotypes, including synaptic and neuronal deficits, in mouse models of autism spectrum disorder (ASD). Additionally, HU-53 has shown potential in oncology, where it inhibits neuroblastoma and glioblastoma tumor growth by suppressing the NO-mTOR signaling axis, leading to decreased tumor weight and volume, and reduced cell proliferation.
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on HU-53.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HU-53.